Sign In
Buy BEAM
$29.55
+0.590 (+2.04%)
At Close: Jun 03, 2026
Beam Therapeutics Inc. (BEAM) Reports Q3 Loss, Misses Revenue Estimates
08:28am, Monday, 08'th Nov 2021
Beam Therapeutics Inc. (BEAM) delivered earnings and revenue surprises of 46.15% and -95.19%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the s
If I Could Only Own 1 Healthcare Stock, This Is What It Would Be
09:25am, Thursday, 21'st Oct 2021
Investing gets simple if you have to put all of your eggs in one basket.
Sana Obtains License To Beam Therapeutics' CRISPR Cas12b Gene Editing Technology
03:55pm, Tuesday, 19'th Oct 2021
Sana Biotechnology Inc (NASDAQ: SANA) has secured non-exclusive commercial rights to Beam Therapeutics Inc's (NASDAQ: BEAM) CRISPR Cas12b nuclease system for certain ex vivo engineered cell the
Findings Show Base Editing Leads to Elimination of Disease Phenotype in an In Vivo Model Findings Show Base Editing Leads to Elimination of Disease Phenotype in an In Vivo Model
Why Shares of Allogene Therapeutics, Beam Therapeutics, Intellia Therapeutics, and Schrödinger Are Volatile This Week
09:57am, Friday, 15'th Oct 2021
A key gene-editing readout had Cathie Wood shuffling her portfolio.
4 Biotechs to Watch Amid Rising Prominence of Gene Therapies
12:38pm, Thursday, 14'th Oct 2021
Here we discuss four biotech companies, CRSP, EDIT, SRPT and BEAM, that have the potential to gain from their promising gene therapy pipeline candidates.
Cathie Wood Goes Dumpster Diving: 3 Sagging Stocks She Just Bought
05:43am, Tuesday, 12'th Oct 2021
All three of these growth stocks have been tumbling, but that doesn't frighten off ARK Invest's top stock picker.
Beam Therapeutics: This Technology Should Be Part Of Every Investor's Portfolio
10:24am, Friday, 01'st Oct 2021
Gene-editing companies are fighting for their share in a future multi-trillion dollar market. BEAM has a great management team, the best gene-editing technology, and follows a very smart platform lice
CAMBRIDGE, Mass., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the
Beam Therapeutics to Participate in the Chardan Virtual 5th Annual Genetic Medicines Conference
06:30am, Tuesday, 28'th Sep 2021
CAMBRIDGE, Mass., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that Jo
Beam Therapeutics' Base Editors Show Encouraging Preclinical Action In HBV Infection
09:53am, Monday, 27'th Sep 2021
Beam Therapeutics Inc (NASDAQ: BEAM) has announced preclinical data for its cytosine base editors (CBEs). The data demonstrate the potential of CBEs to reduce viral markers, including hepatitis B s
Data to be Presented During an Oral Presentation at the 2021 International HBV Meeting Data to be Presented During an Oral Presentation at the 2021 International HBV Meeting
Beam Therapeutics' Formulated LNP Show Tolerance, Early Storage Stability In Animal Studies
07:42am, Thursday, 23'rd Sep 2021
Beam Therapeutics Inc (NASDAQ: BEAM) has announced new preclinical data for novel lipid nanoparticle (LNP) formulations for in vivo liver editing. The Company says that continued optimization o
CAMBRIDGE, Mass., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced new pre
7 Gene Editing Stocks Promising to Change our DNA
12:45pm, Wednesday, 15'th Sep 2021
Gene editing stocks will take off as the underlying tech moves from fiction to fact and companies put their products on the market. The post 7 Gene Editing Stocks Promising to Change our DNA appeared
